Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
Abstract Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia,...
Main Authors: | Satoko Oka, Kazuo Ono |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4287 |
Similar Items
-
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
by: Richardson PG, et al.
Published: (2017-08-01) -
Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
by: Leo Reap, DO, et al.
Published: (2020-01-01) -
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib Against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
by: Margot S.F. Roeten, et al.
Published: (2021-03-01) -
Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01) -
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells
by: Masanobu Tsubaki, et al.
Published: (2021-01-01)